WallStreetZenWallStreetZen

NYSEMKT: CANF
Can Fite Biopharma Ltd Stock

$3.14+0.38 (+13.77%)
Updated Jun 12, 2024
CANF Price
$3.14
Fair Value Price
N/A
Market Cap
$12.81M
52 Week Low
$1.81
52 Week High
$3.33
P/E
-1.05x
P/B
2.05x
P/S
12.62x
PEG
N/A
Dividend Yield
N/A
Revenue
$743.00k
Earnings
-$7.63M
Gross Margin
100%
Operating Margin
-1,027.46%
Profit Margin
-1,027.5%
Debt to Equity
0.6
Operating Cash Flow
-$8M
Beta
0.3
Next Earnings
Jun 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A

CANF Overview

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CANF scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CANF is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CANF is good value based on its book value relative to its share price (2.05x), compared to the US Biotechnology industry average (6.31x)
P/B vs Industry Valuation
CANF is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CANF due diligence checks available for Premium users.

Be the first to know about important CANF news, forecast changes, insider trades & much more!

CANF News

Valuation

CANF price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.05x
Industry
-9.14x
Market
30.03x

CANF price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.05x
Industry
6.31x
CANF is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CANF's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
CANF's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CANF's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$10.0M
Liabilities
$3.7M
Debt to equity
0.6
CANF's short-term assets ($9.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CANF's short-term assets ($9.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CANF's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CANF's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
CANF's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CANF vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CANF$12.81M+13.77%-1.05x2.05x
IMRN$12.76M-0.88%-5.03x1.09x
DOMH$12.89M-1.38%-0.46x0.27x
EVAX$13.04M+7.17%-0.42x-2.76x
PSTV$12.49M+0.92%-0.72x-2.58x

Can Fite Biopharma Stock FAQ

What is Can Fite Biopharma's quote symbol?

(NYSEMKT: CANF) Can Fite Biopharma trades on the NYSEMKT under the ticker symbol CANF. Can Fite Biopharma stock quotes can also be displayed as NYSEMKT: CANF.

If you're new to stock investing, here's how to buy Can Fite Biopharma stock.

What is the 52 week high and low for Can Fite Biopharma (NYSEMKT: CANF)?

(NYSEMKT: CANF) Can Fite Biopharma's 52-week high was $3.33, and its 52-week low was $1.81. It is currently -5.71% from its 52-week high and 73.48% from its 52-week low.

How much is Can Fite Biopharma stock worth today?

(NYSEMKT: CANF) Can Fite Biopharma currently has 1,359,837,393 outstanding shares. With Can Fite Biopharma stock trading at $3.14 per share, the total value of Can Fite Biopharma stock (market capitalization) is $12.81M.

Can Fite Biopharma stock was originally listed at a price of $825.00 in Nov 6, 2012. If you had invested in Can Fite Biopharma stock at $825.00, your return over the last 11 years would have been -99.62%, for an annualized return of -39.74% (not including any dividends or dividend reinvestments).

How much is Can Fite Biopharma's stock price per share?

(NYSEMKT: CANF) Can Fite Biopharma stock price per share is $3.14 today (as of Jun 12, 2024).

What is Can Fite Biopharma's Market Cap?

(NYSEMKT: CANF) Can Fite Biopharma's market cap is $12.81M, as of Jun 13, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Can Fite Biopharma's market cap is calculated by multiplying CANF's current stock price of $3.14 by CANF's total outstanding shares of 1,359,837,393.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.